Abstract：Objective: To explore clinical effect of zoledronic acid injection combined with calcium carbonate D3 tablet in the treatment of postmenopausal osteoporosis (PMO). Methods: 124 patients with PMO admitted to our hospital from February 2015 to February 2017 were randomly divided into observation group (n=62) and control group (n=62). The patients in the control group were given oral calcium carbonate D3 tablets and the patients in the observation group were given oral calcium carbonate D3 combined with zoledronic acid injection. All patients were treated for 12 months. The clinical effects bone mineral density (BMD), visual analogue scale (VAS), the change of creatinine ratio (U-Ca/Cr)] before and after treatment and the incidence of adverse reactions were compared between the two groups. Results: After 12 months of treatment, the total effective rate of the observation group was 93.5% (58/62) significantly higher than that of the control group [80.6% (50/62), P<0.05]. Compared with before treatment, the BMD value of each position (femoral neck, total hip, Wards triangle, lumbar L2 ~ 4) in the two groups increased significantly after treatment (P<0.05), and the BMD value in the observation group increased more significantly (P<0.05). After treatment, the VAS score, serum IL-6, BALP, TRACP-5b concentration and urinary U-Ca/Cr value of the two groups were significantly lower than those before treatment (P<0.05), and the observation group decreased more significantly (P<0.05). The adverse reaction rate of the observation group was 9.7% (6/62) compared with the control group [4.8% (3/62)]. There was no significant difference (P>0.05). Conclusion: Zoledronic acid injection combined with calcium carbonate D3 tablets can effectively improve the symptoms of patients with PMO, and enhance bone quality, correct the imbalance of bone remodeling. It has the significant curative effect and high safety.
[1] Venugopal Y, Sfwm H, Musa N, et al. Maintenance vitamin D3 dosage requirements in Chinese women with post menopausal osteoporosis living in the tropics.[J]. Asia Pac Clin Nutr, 2017, 26(3):412~420. [2] 许海波, 马一鸣,方志祥.绝经后骨质疏松患者发生骨折的相关因素分析[J].浙江预防医学,2017,29(9):944~945. [3] Alami S, Hervouet L, Poiraudeau S, et al. Barriers to effective postmenopausal osteoporosis treatment: a qualitative study of patients' and practitioners' views[J]. PLoS One, 2016, 11(6):e0158365. [4] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2017)[J].中华骨质疏松和骨矿盐疾病杂志,2017,20(5):413,443. [5] Wang C. Efficacy and safety of zoledronic acid for treatment of postmenopausal osteoporosis: a meta-analysis of randomized controlled trials[J]. Am Ther, 2017, 24(5):e544~e552. [6] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊治指南(2011年)[J].中华骨质疏松和骨矿盐疾病杂志,2011,4(1):2,17. [7] 孙传兴.临床疾病诊断依据治愈好转标准[M].第2版.北京:人民军医出版社,2002.132. [8] 曹卉娟,邢建民,刘建平.视觉模拟评分法在症状类结局评价测量中的应用[J].中医杂志,2009,50(7):600~602. [9] 周建烈,刘忠厚.补充钙和维生素D防治骨质疏松症的全球临床指南进展[J].中国骨质疏松杂志,2017(3):371~380. [10] 骆楚君,李敏娟,钟黛云,等.双膦酸盐治疗绝经后骨质疏松的系统评价再评价[J].中国临床药理学杂志,2016,32(6):557~559. [11] 郭德立,刘欣,李涛,等.唑来膦酸注射液联合碳酸钙D3片治疗老年女性骨质疏松的临床研究[J].现代药物与临床,2017,32(2):275~279. [12] 马玉红.唑来膦酸注射液对骨质疏松大鼠模型的治疗效果分析[J].安徽医药,2016,20(2):246~248.
2018, Vol. 24 
冀公网安备13080202000677号